Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and ext...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-05-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1420-3049/23/5/1190 |
| _version_ | 1819091637346762752 |
|---|---|
| author | Lorena Simón-Gracia Hedi Hunt Tambet Teesalu |
| author_facet | Lorena Simón-Gracia Hedi Hunt Tambet Teesalu |
| author_sort | Lorena Simón-Gracia |
| collection | DOAJ |
| description | Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improve their anticancer efficacy. However, IP-administered chemotherapeutics have a short residence time in the IP space, and are not tumor selective. An increasing body of work suggests that functionalization of drugs and nanoparticles with targeting peptides increases their peritoneal retention and provides a robust and specific tumor binding and penetration that translates into improved therapeutic response. Here we review the progress in affinity targeting of intraperitoneal anticancer compounds, imaging agents and nanoparticles with tumor-homing peptides. We review classes of tumor-homing peptides relevant for PC targeting, payloads for peptide-guided precision delivery, applications for targeted compounds, and the effects of nanoformulation of drugs and imaging agents on affinity-based tumor delivery. |
| first_indexed | 2024-12-21T22:42:53Z |
| format | Article |
| id | doaj.art-f52bb84fe15b4e59b57b7e329a852404 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-12-21T22:42:53Z |
| publishDate | 2018-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-f52bb84fe15b4e59b57b7e329a8524042022-12-21T18:47:48ZengMDPI AGMolecules1420-30492018-05-01235119010.3390/molecules23051190molecules23051190Peritoneal Carcinomatosis Targeting with Tumor Homing PeptidesLorena Simón-Gracia0Hedi Hunt1Tambet Teesalu2Laboratory of Cancer Biology, Institute of Biomedicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, EstoniaLaboratory of Cancer Biology, Institute of Biomedicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, EstoniaLaboratory of Cancer Biology, Institute of Biomedicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, EstoniaOver recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improve their anticancer efficacy. However, IP-administered chemotherapeutics have a short residence time in the IP space, and are not tumor selective. An increasing body of work suggests that functionalization of drugs and nanoparticles with targeting peptides increases their peritoneal retention and provides a robust and specific tumor binding and penetration that translates into improved therapeutic response. Here we review the progress in affinity targeting of intraperitoneal anticancer compounds, imaging agents and nanoparticles with tumor-homing peptides. We review classes of tumor-homing peptides relevant for PC targeting, payloads for peptide-guided precision delivery, applications for targeted compounds, and the effects of nanoformulation of drugs and imaging agents on affinity-based tumor delivery.http://www.mdpi.com/1420-3049/23/5/1190homing peptideperitoneal carcinomatosisintraperitoneal chemotherapyp32neuropilin-1integrinshyaluronan |
| spellingShingle | Lorena Simón-Gracia Hedi Hunt Tambet Teesalu Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides Molecules homing peptide peritoneal carcinomatosis intraperitoneal chemotherapy p32 neuropilin-1 integrins hyaluronan |
| title | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| title_full | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| title_fullStr | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| title_full_unstemmed | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| title_short | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| title_sort | peritoneal carcinomatosis targeting with tumor homing peptides |
| topic | homing peptide peritoneal carcinomatosis intraperitoneal chemotherapy p32 neuropilin-1 integrins hyaluronan |
| url | http://www.mdpi.com/1420-3049/23/5/1190 |
| work_keys_str_mv | AT lorenasimongracia peritonealcarcinomatosistargetingwithtumorhomingpeptides AT hedihunt peritonealcarcinomatosistargetingwithtumorhomingpeptides AT tambetteesalu peritonealcarcinomatosistargetingwithtumorhomingpeptides |